HUTCHMED (Germany) Top Insiders
H7T2 Stock | EUR 2.76 0.06 2.22% |
HUTCHMED employs about 2.1 K people. The company is managed by 13 executives with a total tenure of roughly 115 years, averaging almost 8.0 years of service per executive, having 162.31 employees per reported executive. Examination of HUTCHMED's management performance can provide insight into the company performance.
Christian Hogg CEO Chief Executive Officer, Executive Director |
HUTCHMED |
HUTCHMED Management Team Effectiveness
The company has return on total asset (ROA) of (0.1932) % which means that it has lost $0.1932 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2472) %, meaning that it generated substantial loss on money invested by shareholders. HUTCHMED's management efficiency ratios could be used to measure how well HUTCHMED manages its routine affairs as well as how well it operates its assets and liabilities.HUTCHMED Workforce Comparison
HUTCHMED LS 1 is one of the top stocks in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 17,175. HUTCHMED retains roughly 2,110 in number of employees claiming about 12% of stocks in Biotechnology industry.
The company has Profit Margin (PM) of (0.64) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.95) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.95. HUTCHMED LS 1 Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. HUTCHMED LS 1 Price Series Summation is a cross summation of HUTCHMED price series and its benchmark/peer.
HUTCHMED Notable Stakeholders
A HUTCHMED stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as HUTCHMED often face trade-offs trying to please all of them. HUTCHMED's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting HUTCHMED's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Christian Hogg | Chief Executive Officer, Executive Director | Profile | |
Chig Cheng | Chief Financial Officer, Executive Director | Profile | |
Edith Shih | Company Secretary, Non-Executive Director | Profile | |
May Wang | Senior Vice President - business development & strategic alliances | Profile | |
Mark Lee | Senior Vice President - Corporate Finance & Development | Profile | |
Karen Ferrante | Independent Non-Executive Director | Profile | |
Weiguo Su | Chief Scientific Officer, Executive Director | Profile | |
Shu Mok | Independent Non-Executive Director | Profile | |
Graeme Jack | Independent Non-Executive Director | Profile | |
Zhenping Wu | Senior Vice President - Pharmaceutical Sciences | Profile | |
Dan Eldar | Non-Executive Director | Profile | |
Simon To | Executive Chairman of the Board | Profile | |
Paul Carter | Senior Independent Non-Executive Director | Profile |
About HUTCHMED Management Performance
The success or failure of an entity such as HUTCHMED LS 1 often depends on how effective the management is. HUTCHMED management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of HUTCHMED management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the HUTCHMED management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
HUTCHMED Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. HUTCHMED Limited was incorporated in 2000 and is headquartered in Central, Hong Kong. HUTCHMED operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 1280 people.
HUTCHMED Workforce Analysis
Traditionally, organizations such as HUTCHMED use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare HUTCHMED within its industry.HUTCHMED Manpower Efficiency
Return on HUTCHMED Manpower
Revenue Per Employee | 190K | |
Revenue Per Executive | 30.8M | |
Net Loss Per Employee | 84.6K | |
Net Loss Per Executive | 13.7M |
Complementary Tools for HUTCHMED Stock analysis
When running HUTCHMED's price analysis, check to measure HUTCHMED's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HUTCHMED is operating at the current time. Most of HUTCHMED's value examination focuses on studying past and present price action to predict the probability of HUTCHMED's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HUTCHMED's price. Additionally, you may evaluate how the addition of HUTCHMED to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |